Kantarjian et al 1 present their randomized study of 3 schedules of low-dose decitabine in patients with higher-risk myelodysplastic syndrome/chronic monomyelocytic leukemia (MDS/CMML) reporting a high complete remission (CR) rate. This comprehensive clinical trial along with its biologic correlates represents a significant addition to the therapeutic choices available for patients with MDS. For the clinician to make an informed decision about the use of decitabine versus azcitidine, it would be helpful if the authors address the following issues that were left rather ambiguous.
No takes yet. Share an insight, caveat, or question.
Raza et al. (2006) studied this question.